NancyLeeBartlettMD

Hematologic Oncology

Professor, Internal Medicine, Washington University School of Medicine

Overview of Dr. Bartlett

Dr. Nancy Bartlett is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Siteman Cancer Center, Barnes-Jewish Hospital, and Barnes-Jewish West County Hospital. She received her medical degree from Washington University School of Medicine in St. Louis and has been in practice 31 years. Dr. Bartlett accepts several types of health insurance, listed below. She is one of 102 doctors at Barnes-Jewish Hospital and one of 41 doctors at Barnes-Jewish West County Hospital who specialize in Oncology.

Office
4921 Parkview Pl
7th Floor
Saint Louis, MO 63110
Book by Phone+1(314) 748-1462
Fax(314) 361-3192
Is this information wrong?

Education & Training

Stanford UniversityFellowship, Medical Oncology, 1990 - 1993
UCSFInternship, Internal Medicine, 1986 - 1987
Washington University School of Medicine in St. LouisClass of 1986

Certifications & Licensure

MO State Medical License 1993 - 2022
CA State Medical License 1988 - Present
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 01Bruce Cheson
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refra Start of enrollment: 2014 Oct 01Carson, K.,Ai, W.
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Sep 01Wagner-Johnston, N.D.,Cashen, A.,Fehniger, T.A.,Ward, J.P.,Bartlett, N.L.,Carson, K.R.
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 01Kanate, A.S.,Tolentino, A.R.,Menter, A.,Bseiso, A.W.,Conlin, A.K.,Sehgal, A.R.,Karnad, A.B.,Klein, A.K.,Mato, A.R.,Vemula, A.Y.,Shipstone, A.,Kasimis, B.S.,Holkova, B.,Marchello, B.T.,Friday, B.E.,DiCarlo...
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2013 Dec 01Jennifer Woyach
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 01Bartlett, N.L.,Puvvada, S.,Flinn, I.W.,Blum, K.A.,Richards, K.L.,Gerecitano, J.F.,Goy, A.H.
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01Boyd, T.E.,Bartlett, N.L.,Holkova, B.,Ansell, S.M.,Halwani, A.S.,Burke, J.M.,Fayad, L.E.,Advani, R.H.,Kolibaba, K.S.,Budde, L.E.,Seetharam, M.,Yasenchak, C.A.,Knapp, M.,Farber, C.M.
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 01Forero-Torres, A.,Advani, R.,Foss, F.,Dang, N.H.,Sarriera, J.,Link, B.,Reyes, R.,Haddad, P.,Kimball, A.,Jacobsen, E.,Kaminski, M.,Kubiak, K.,Bartlett, N.,Feldman, T.,Battini, R.,Horwitz, S.,Ruan, J.,O'Con...
A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma Start of enrollment: 2012 Jul 01Wagner-Johnston, N.,Goyal, S.
A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients â‰¤ 65 Years of Age Wi Start of enrollment: 2011 Nov 01Bartlett, N.L.,Beardell, F.,Bernstein, S.H.,Dakhil, S.R.,Flynn, P.J.,Friedberg, J.W.,Gorak, E.J.,Gross, H.M.,Inoue, Y.,Le-Lindqwister, N.A.,Mowat, R.B.,Person, C.,Rivkin, S.E.,Wender, D.B.
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2011 Oct 01Blum, K.,Blum, K.A.
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2011 Sep 01Atkins, J.N.,Bartlett, N.L.,Berenberg, J.L.,Chapman, R.A.,Dakhil, S.R.,Flynn, P.J.,Friedberg, J.W.,Gaur, R.,Giguere, J.K.,Grimm, R.A.,Gross, H.M.,Le-Lindqwister, N.A.,Lord, R.S.,Marchello, B.T.,Menter, A....
A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2011 Aug 01Bates, J.(.,Biggers, S.,Braley, L.,Brockington, D.,Choudhury, S.,Copeland, A.(.,Flanagan, B.,Ford, P.,Grove, L.,Larson, S.,Lowe, T.,Martinez, I.,Murphy, J.,Stoeppler-Biege, K.,Taylor, P.,Zelonis, S.
A Phase II Trial of Ofatumumab (CALGB IND #) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Start of enrollment: 2011 Aug 01Bartlett, N.L.,Briccetti, F.M.,Grubbs, S.S.,Le-Lindqwister, N.A.,Padula, G.D.,Rosenbaum, C.A.,Watson, P.R.
A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma Start of enrollment: 2011 Apr 01Devine, S.,Fehniger, T.
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma Start of enrollment: 2011 Apr 01Bartlett, N.L.,Blum, K.A.,Ghiuzeli, C.M.,Grimm, R.A.,Kirshner, J.J.,Nattam, S.R.,Watson, P.R.
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL) Start of enrollment: 2010 Sep 01Atkins, J.N.,Bartlett, N.L.,LaCasce, A.S.
Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma Start of enrollment: 2010 Jul 01Atkins, J.N.,Bartlett, N.L.,Bseiso, A.W.,Chi, D.,Craig, M.D.,Dakhil, S.R.,Ellerton, J.A.,Evens, A.M.,Friedberg, J.W.,Jillella, A.P.,LaCasce, A.S.,Rivkin, S.E.,Rubinstein, P.G.,Straus, D.J.,Wender, D.B.
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging Start of enrollment: 2009 Jul 01Atkins, J.N.,Bartlett, N.L.,Bearden, J.D.,Beck, J.T.,Berenberg, J.L.,Bseiso, A.W.,Bury, M.J.,Carolla, R.L.,Cathcart-Rake, W.F.,Craig, M.D.,Dakhil, S.R.,Ellerton, J.A.,Epner, E.M.,Evens, A.M.,Fehrenbacher,...
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 01Stockerl-Goldstein, K.
A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 01Ansari, R.H.,Assouline, S.,Atkins, J.N.,Averbook, B.J.,Bank, B.B.,Bartlett, N.L.,Bayer, G.K.,Behrens, R.J.,Bociek, R.,Byrd, J.C.,Catcher, C.H.,Cathcart-Rake, W.F.,Couban, S.,Craig, M.D.,Entmacher, M.S.,Fi...
A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid ™, CC-5013) (NSC #703813) for Relapsed/Refractory Mantle Cell Lymphoma Start of enrollment: 2007 Nov 01Atkins, J.N.,Bartlett, N.L.,Bury, M.J.,Chitneni, S.R.,Grant, B.W.,Grubbs, S.S.,Kirshner, J.J.,Koh, H.A.,LaCasce, A.S.,Morrison, V.A.,Nattam, S.R.,Office, C.T.,Openshaw, T.H.,Service, C.I.,Sleeper, A.,Wats...
Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01Bartlett, N.,Duvic, M.,Fleischer, A.B.,Forero-Torres, A.,Foss, F.,Gabrail, N.,Geskin, L.,Goy, A.,Kim, Y.,Korman, N.J.,Olsen, E.,Parker, S.S.,Prince, M.,Shustov, A.R.,Turturro, F.,Wood, G.S.
A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies. Start of enrollment: 2006 Nov 01Bartlett, N.,Forero, A.,Kennedy, D.,Leonard, J.,Younes, A.
A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory Start of enrollment: 2006 Mar 01Bartlett, N.L.,Briccetti, F.M.,Catcher, C.H.,Ellerton, J.A.,Gaur, R.,Giguere, J.K.,Grant, B.W.,Kirshner, J.J.,Koh, H.A.,Kugler, J.W.,Langdon, R.M.,Leonard, J.P.,Lutzky, J.,Watson, P.R.
Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas Start of enrollment: 2005 May 01Abramson, J.S.,Ansari, R.H.,Atkins, J.N.,Bahadini, B.,Barhamand, F.B.,Bartlett, N.L.,Behrens, R.J.,Bseiso, A.W.,Colman, L.K.,Craig, M.D.,Dakhil, S.R.,Ellerton, J.A.,Epner, E.M.,Fadell, A.J.,Fisher, R.I.,G...
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01Perrault-Gray, A.,Ayala, A.,Mohrbacher, A.,Freedman, A.,Grant, A.,Hayes-Lattin, B.,Wood, C.,Redfern, C.,Aboulafia, D.M.,Flinn, I.W.,Chang, J.,Castro, J.E.,Lucas, J.B.,Zhang, J.,Stephenson, J.J.,Martin, J....
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 01Bartlett, N.L.
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Start of enrollment: 2000 Nov 01Connors, J.M.,Bartlett, N.L.,Fisher, R.I.,Horning, S.J.
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Start of enrollment: 2000 Jul 01Bartlett, N.L.
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2000 Jul 01Bartlett, N.L.
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Start of enrollment: 1996 Nov 01Bartlett, N.L.
The CALGB Leukemia Tissue Bank Start of enrollment: 1996 May 01Ansari, R.H.,Atkins, J.N.,Bartlett, N.L.,Beardell, F.,Caligiuri, M.A.,Catcher, C.H.,Chitneni, S.R.,Ellerton, J.A.,Gable, P.S.,Gaur, R.,Giguere, J.K.,Grant, B.W.,Grimm, R.A.,Kirshner, J.J.,Koh, H.A.,Kugler...
Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma Start of enrollment: 1996 Apr 01Bartlett, N.L.
Cytogenetic Studies For Previously Untreated AML, ALL or MDS Patients (Companion To CALGB Treatment Studies For Previously Untreated AML, ALL Or MDS Patients) Start of enrollment: 1984 Jun 01Atkins, J.N.,Bartlett, N.L.,Beardell, F.,Bloomfield, C.D.,Bury, M.J.,Chitneni, S.R.,Ellerton, J.A.,Gable, P.S.,Gaur, R.,Giguere, J.K.,Grant, B.W.,Hudson, J.M.,Kirshner, J.J.,Koh, H.A.,Kugler, J.W.,Langdon...
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas John P. Leonard, M.D., Jeremy S. Abramson, M.D., and Sarah Rutherford, M.D.
Molecular Markers Of Chronic Lymphocytic Leukemia Atkins, J.N.,Bartlett, N.L.,Bociek, R.,Byrd, J.C.,Chitneni, S.R.,Grant, B.W.,Gribben, J.G.,Grubbs, S.S.,Heerema, N.,Kirshner, J.J.,Koh, H.A.,Lister, J.,Lyss, A.P.,Nattam, S.R.,Openshaw, T.H.,Radford, J.E....
Join now to see all

Publications & Presentations

PubMed

Protect our children: Hodgkin lymphoma survivors.
Nancy L. Bartlett> ;Blood. 2021 Mar 18
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.
Sambhavi Krishnamoorthy, Armin Ghobadi, Rowena Delos Santos, Joel D. Schilling, Andrew F. Malone, Haris Murad, Nancy L. Bartlett, Tarek Alhamad> ;American Journal of Transplantation. 2021 Feb 1
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Andrew Mehta, Andres Forero-Torres, Ramón García-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez Izqu...> ;Blood. 2020 Nov 19
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Margery Gang, Nancy D. Marin, Pamela Wong, Carly Neal, Lynne Marsala, Mark P. Foster, Timothy Schappe, Wei Meng, Jennifer Tran, Maximilian Schaettler, Marco L. Davila,...> ;Blood. 2020 Nov 12
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/smal...
Graeme Fraser, Asher Chanan-Khan, Fatih Demirkan, Rodrigo Santucci Silva, Sebastian Grosicki, Ann Janssens, Jiri Mayer, Nancy L. Bartlett, Marie Sarah Dilhuydy, Javier...> ;Leukemia & Lymphoma. 2020 Aug 6
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Heiko Schöder, Mei Yin Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary J. Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. C...> ;Blood. 2020 Jun 18
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Munoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim...> ;Blood. 2020 Jun 4
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
Mark Roschewski, Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel, Philip J. Bierman, Deepa Jagadeesh, Ronald T. Mitsuyasu, David ...> ;Journal of Clinical Oncology. 2020 May 26
Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403.
Lawrence D. Kaplan, Matthew J. Maurer, Wendy Stock, Nancy L. Bartlett, Noreen Fulton, Adam Pettinger, John C. Byrd, Kristie A. Blum, Ann S. LaCasce, Eric D. Hsi, Yi Ti...> ;American Journal of Hematology. 2020 Mar 13
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Reid W. Merryman, Natasha Catherine Edwin, Robert A. Redd, Jad Bsat, Matthew L Chase, Ann S. LaCasce, Arnold S. Freedman, Caron A. Jacobson, David C. Fisher, Samuel Ng...> ;Blood Advances. 2020 Mar 10
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Rec...
Stephen J. Schuster, Nancy L. Bartlett, Sarit Assouline, Sung-Soo Yoon, Francesc Bosch, Laurie H. Sehn, Chan Yoon Cheah, Mazyar Shadman, Gareth P. Gregory, Matthew Ku,...> ;Blood. 2019 Nov 13
2 citations
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CA...
Kristie A. Blum, Mei Yin Polley, Sin-Ho Jung, Travis J. Dockter, Sarah A. Anderson, Eric D. Hsi, Nina D. Wagner-Johnston, Beth Christian, Jim Atkins, Bruce D. Cheson, ...> ;Cancer. 2019 Oct 1
Erratum: A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)
Peter Martin, Nancy L. Bartlett, Kristie A. Blum> ;Blood. 2019 Sep 12
34 citations
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b...
Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett, Andrew Mehta, Gilles Salles, Corinne Haioun, Javier Munoz, Andy I. Chen, Kathryn S. Kolibaba, Dan Lu, Mark Yan, El...> ;Lancet Oncology. 2019 Jul 1
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis Fayad, ...> ;Journal of The National Comprehensive Cancer Network. 2019 Jun 1
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial
Silvia Maria Lavezzi, Jan de Jong, Martine Neyens, Paula Cramer, Fatih Demirkan, Graeme Fraser, Nancy L. Bartlett, Marie-Sarah Dilhuydy, Javier Loscertales, Abraham Av...> ;Pharmaceutical Research. 2019 May 1
7 citations
Parameters for Validating a Hospital Pneumatic Tube System
Christopher W Farnsworth, Daniel M. Webber, James A Krekeler, Melissa M. Budelier, Nancy L. Bartlett, Ann M. Gronowski> ;Clinical Chemistry. 2019 May 1
8 citations
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Eric D. Hsi, Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali M. Smith, Brad S. Kahl, John P. Leonard, Andrew M. Evens, David Scot...> ;Blood. 2019 Apr 18
2 citations
Chemotherapy-Induced First Bite Syndrome: A Case Report in a Patient With Hodgkin Lymphoma.
Carla V. Valenzuela, Nancy L. Bartlett, Joseph P. Bradley> ;Ear, nose, & throat journal. 2019 Apr 8
56 citations
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 5...
Nancy L. Bartlett, Wyndham H. Wilson, Sin-Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi Pederson, Mei Yin Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, ...> ;Journal of Clinical Oncology. 2019 Apr 2
32 citations
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme Fraser, Paula Cramer, Fatih Demirkan, R. Santucci Silva, Sebastian Grosicki, Alexander Pristupa, Ann Janssens, Jiří Mayer, Nancy L. Bartlett, Marie-Sarah Dilhuy...> ;Leukemia. 2019 Apr 1
2 citations
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
Cara A. Rosenbaum, Sin-Ho Jung, Brandelyn N. Pitcher, Nancy L. Bartlett, Sonali M. Smith, Eric D. Hsi, Nina D. Wagner-Johnston, Sachdev P. Thomas, John P. Leonard, Bru...> ;British Journal of Haematology. 2019 Apr 1
14 citations
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert T. Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan ...> ;Clinical Cancer Research. 2019 Mar 15
21 citations
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven I. Park, Kami J. Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio...> ;Blood. 2019 Mar 14
1 citations
Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound‐Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine‐Needle Aspiration of Peripheral Lymph Nodes
Monica R. Drylewicz, Marcus Watkins, Anup S. Shetty, Michael Lin, Amber Salter, Nancy L. Bartlett, William D. Middleton, Motoyo Yano> ;Journal of Ultrasound in Medicine. 2019 Mar 1
Join now to see all

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study
Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine
Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...
Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
Join now to see all

Abstracts/Posters

North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as...
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Lymphoma & Myeloma 2012: An International Congress on Hematologic Malignancies
Imedex, Naples, Florida - 10/25/2012
2012 American Society of Hematology State-of-the-Art Symposium
American Society of Hematology (ASH), Hollywood, California - 10/12/2012
Join now to see all

Press Mentions

Cancer Clinical Trial Access Expands in St. Louis Area Thanks to $7.8m to Siteman Cancer CenterAugust 2nd, 2019
Siteman Cancer Center Awarded $7.8 Million to Expand Clinical Trials AccessAugust 1st, 2019
Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCLJuly 1st, 2019
Join now to see all

Grant Support

Wumc Cancer And Leukemia Group BNational Cancer Institute2009–2012
Data And Safety MonitoringNational Cancer Institute2010–2011
Wumc-Cancer And Leukemia Group BNational Cancer Institute2003–2008
Quality Assurance And Safety MonitoringNational Cancer Institute2004
24hr Infusion Of Hmr1275 In Fludarabine--B Cell LeukemiaNational Center For Research Resources2000–2002
Wusm Cancer And Leukemia Group BNational Cancer Institute1998–2002
Coadmin Rising Oral Gg918 Dose Levels (GH120918) W/ Doxorubicin In Cancer PTSNational Center For Research Resources1998–1999

Hospital Affiliations

Siteman Cancer CenterSaint Louis, Missouri
Barnes-Jewish HospitalSaint Louis, Missouri
Barnes-Jewish West County HospitalSaint Louis, Missouri

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Massachusetts Blue Care Elect PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment